Catalysta Ventures
1
1
0.09
1
- Stages of investment
- Areas of investment
Summary
Catalysta Ventures appeared to be the VC, which was created in 2010. The main department of described VC is located in the Durham. The venture was found in North America in United States.
Among the various public portfolio startups of the fund, we may underline PhaseBio Pharmaceuticals For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most successful fund investment fields, there are Medical Device, Medical.
The typical case for the fund is to invest in rounds with 1 participant. In the next rounds fund is usually obtained by Johnson & Johnson Development Corporation, Hatteras Venture Partners, Fletcher Spaght, Inc..
The top amount of exits for fund were in 2018. The high activity for fund was in 2002. The fund is constantly included in less than 2 deals per year.
Investments analytics
Analytics
- Total investments
- 1
- Lead investments
- 0
- Exits
- 1
- Rounds per year
- 0.09
- Investments by industry
- Pharmaceutical (1)
- Medical Device (1)
- Biotechnology (1)
- Medical (1)
- Investments by region
-
- United States (1)
- Peak activity year
- 2002
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 19
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| PhaseBio Pharmaceuticals | 25 Feb 2002 | Biotechnology, Medical Device, Medical, Pharmaceutical | Early Stage Venture | 0 | United States, Pennsylvania |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.